Skip to main content
SpringerLink
Log in

Drug Therapy in Haemodialysis Patients

Special Considerations in the Elderly

  • Review Article
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

End-stage renal disease (ESRD) is the stage of renal failure at which an individual requires dialysis therapy or a renal transplant to survive. The prevalence of ESRD is disproportionately higher among patients aged >65 years, and the average age of new ESRD patients is continually rising in the US Medicare population. Medication management in this population is challenging because of the combination of multiple comorbid disease states, a plethora of medications and the added dimension of dialysis therapy, as well as pharmacokinetic and pharmacodynamic changes attributable to the aging process.

Cardiovascular disorders such as hypertension, coronary artery disease, congestive heart failure and arrhythmias are common in elderly patients with ESRD, and account for most of the deaths in this population. Constipation is common in patients aged >65 years, and its incidence is even higher among those receiving dialysis.

Pain management is of particular concern because elderly dialysis patients are frequently prescribed inappropriate pain relief regimens. Many healthcare practitioners do not realise that patients with uraemia are at a higher risk of bleeding caused by nonsteroidal anti-inflammatory drugs than are patients with normal renal function. In addition, most practitioners do not appreciate that virtually all opioids (narcotics) and their active metabolites accumulate in patients with renal failure, leading to an increased risk of narcosis.

Infectious complications are frequent in the ESRD population, with dialysis access infections and pneumonia being the 2 most common infections seen in hospitalised patients receiving dialysis treatment. The establishment of vaccination programmes for the prevention of hepatitis B, influenza and pneumococcal infections is important because of the increased risk of these diseases in this population. Unfortunately, these high-risk patients display, in general, a decreased immunogenic response to vaccinations.

This article addresses some of the practical issues that surround the medication management or prevention of these particular diseases in elderly patients undergoing haemodialysis. Specifically, we discuss the pharmacokinetic and pharmacodynamic changes that occur with specific medications in such patients. Drug dialysability is also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. US Renal Data System (USRDS). USRDS 1997 annual data report. Bethesda (MD): The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1997

    Google Scholar 

  2. Holzgreve H, Middeke M. Treatment of hypertension in the elderly. Drugs 1993; 46Suppl. 2: 24–31

    Article  PubMed  Google Scholar 

  3. Salem MM. Hypertension in the hemodialysis population: a survey of 649 patients. Am J Kidney Dis 1995; 26(3): 461–8

    Article  PubMed  CAS  Google Scholar 

  4. Zamara M, Raij L. The effects of various anti-hypertensive agents on cardiovascular risk factors in patients with renal failure. Am J Kidney Dis 1993; 21 (5 Suppl. 2): 100–7

    Google Scholar 

  5. Ritz E, Koch M. Morbidity and mortality due to hypertension in patients with renal failure. Am J Kidney Dis 1993; 21 (5 Suppl. 2): 113–8

    PubMed  CAS  Google Scholar 

  6. Campese VM, Chervu I. Hypertension in dialysis subjects. In: Henrich WL, editor. Principles and practice of dialysis. Baltimore (MD): Williams and Wilkins, 1994: 148–69

    Google Scholar 

  7. Faubert PF, Porush JG. Managing hypertension in chronic renal disease. Geriatrics 1987; 42: 49–58

    PubMed  CAS  Google Scholar 

  8. Lindner A, Gagne E-R, Zingraff J, et al. A circulating inhibitor of the RBC membrane calcium pump in chronic renal failure. Kidney Int 1992; 42: 1328–35

    Article  PubMed  CAS  Google Scholar 

  9. Ritz E, Koomans HA. New insights into mechanisms of blood pressure regulation in patients with uraemia. Nephrol Dial Transplant 1996; 11Suppl. 2: 52–9

    Article  PubMed  Google Scholar 

  10. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC VI). Bethesda (MD): National Institutes of Health, 1997 Nov: NIH Pub. No. 98-4080

    Google Scholar 

  11. Mees EJD. Volaemia and blood pressure: have old truths been forgotten? Nephrol Dial Transplant 1995; 10: 1297–8

    PubMed  CAS  Google Scholar 

  12. Charra B, Calemard E, Ruffett M, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41: 1286–91

    Article  PubMed  CAS  Google Scholar 

  13. Lowenthal DT, Saris SD, Paran E, et al. The use of transdermal clonidine in the hypertensive patient with chronic renal failure. Clin Nephrol 1993; 39: 37–43

    PubMed  CAS  Google Scholar 

  14. Cheigh JS. What are the unique aspects of antihypertensive therapy in dialysis patients? Semin Dial 1994; 7: 170–2

    Google Scholar 

  15. Fouad-Tarazi F, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med 1995; 99: 604–10

    Article  PubMed  CAS  Google Scholar 

  16. Blowey DL, Williamson B, Gupta I, et al. Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension. Am J Kidney Dis 1996; 28: 132–6

    Article  PubMed  CAS  Google Scholar 

  17. Schaefer KL, Porter JA. Angiotensin II receptor antagonists: the prototype losartan. Ann Pharmacother 1996; 30: 625–35

    PubMed  CAS  Google Scholar 

  18. Parfrey PS. Cardiac and cerebrovascular disease in chronic uremia. Am J Kidney Dis 1993; 21(1): 77–80

    PubMed  CAS  Google Scholar 

  19. Wheeler DC. Cardiovascular disease in patients with chronic renal failure. Lancet 1996; 349: 1673–4

    Article  Google Scholar 

  20. Wheeler DC. Should hyperlipidemia in dialysis patients be treated? Nephrol Dial Transplant 1997; 12: 19–21

    Article  PubMed  CAS  Google Scholar 

  21. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678–82

    Article  PubMed  CAS  Google Scholar 

  22. Groggel GC, Cheung AK, Ellis-Benigni K, et al. Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. Kidney Int 1989; 36: 266–71

    Article  PubMed  CAS  Google Scholar 

  23. Evans JR, Forland SC, Cutler RE. The effect of renal function on the pharmacokinetics of gemfibrozil. J Clin Pharmacol 1987; 27: 994–1000

    PubMed  CAS  Google Scholar 

  24. Chan MK. Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: the role of postheparin lipases in the metabolism of high-density lipoprotein subfractions. Metabolism 1989; 38: 939–45

    Article  PubMed  CAS  Google Scholar 

  25. Elisaf MS, Dardamanis MA, Papagalanis ND, et al. Lipid abnormalities in chronic uremic patients — response to treatment with gemfibrozil. Scand J Urol Nephrol 1993; 27: 101–8

    Article  PubMed  CAS  Google Scholar 

  26. Pasternack A, Vanttinen T, Solakivi T, et al. Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure. Clin Nephrol 1987; 27: 163–8

    PubMed  CAS  Google Scholar 

  27. Vacha GM, Giorcelli G, Siliprandi N, et al. Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: decisive role of low levels of high-density lipoprotein-cholesterol. Am J Clin Nutr 1983; 38: 532–40

    PubMed  CAS  Google Scholar 

  28. Zilleruelo G, Novak M, Hsia SL, et al. Effect of dialysate composition on the lipid response to L-carnitine supplementation. Kidney Int 1989; 36Suppl. 27: S259–63

    Google Scholar 

  29. Yderstraede KB, Pedersen FB, Dragsholt C, et al. The effect of L-carnitine on lipid metabolism in patients on chronic haemodialysis. Nephrol Dial Transplant 1987; 1: 238–41

    PubMed  CAS  Google Scholar 

  30. AAKP (American Association of Kidney Patients) Carnitine Renal Consensus Group. Role of L-carnitine in treating renal dialysis patients. Dial Transplant 1994; 23: 177–81

    Google Scholar 

  31. Catella-Lawson F, FitzGerald GA. Long term aspirin in the prevention of cardiovascular disorders: recent developments and variations on a theme. Drug Saf 1995; 13(2): 69–75

    Article  PubMed  CAS  Google Scholar 

  32. Gaspari F, Viganò G, Orisio S, et al. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest 1987; 79: 1788–97

    Article  PubMed  CAS  Google Scholar 

  33. Silagy CA, McNeil JJ, Donnan GA, et al. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993; 54: 84–9

    Article  PubMed  CAS  Google Scholar 

  34. Ito MK, Smith AR, Lee ML. Ticlopidine: a new platelet aggregation inhibitor. Clin Pharm 1992; 11: 603–17

    PubMed  CAS  Google Scholar 

  35. Saltiel E, Ward A. Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 34: 222–62

    Article  PubMed  CAS  Google Scholar 

  36. Carlson JA, Maesner JE. Fatal neutropenia and thrombocytopenia associated with ticlopidine. Ann Pharmacother 1994; 28: 1236–8

    PubMed  CAS  Google Scholar 

  37. Parfrey PS, Harnett JD, Griffiths SM, et al. Congestive heart failure in dialysis patients. Arch Intern Med 1988; 148: 1519–25

    Article  PubMed  CAS  Google Scholar 

  38. Walker JEC. Congestive heart failure in the elderly. Conn Med 1993; 57(5): 293–8

    PubMed  CAS  Google Scholar 

  39. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Ann Intern Med 1992; 117: 502–10

    PubMed  CAS  Google Scholar 

  40. Neves PL, Silva AP, Bernardo I. Elderly patients in chronic hemodialysis: risk factors for left ventricular hypertrophy. Am J Kidney Dis 1997; 30: 224–8

    Article  PubMed  CAS  Google Scholar 

  41. Goldsmith SR, Dick C. Differentiating systolic from diastolic heart failure: pathophysiologic and therapeutic considerations. Am J Med 1993; 95: 645–55

    Article  PubMed  CAS  Google Scholar 

  42. Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52

    Article  PubMed  CAS  Google Scholar 

  43. Ludden TM, McNay Jr JL, Shepherd AMM, et al. Clinical pharmacokinetics of hydralazine. Clin Pharmacokinet 1982; 7: 185–205

    Article  PubMed  CAS  Google Scholar 

  44. Garg R, Gorlin R, Smith T, et al. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336(8): 525–33

    Article  Google Scholar 

  45. Jusko WJ, Szefler SJ, Goldfarb AL. Pharmacokinetic design of digoxin dosage regimens in relation to renal function. J Clin Pharmacol 1974; 14: 525–35

    PubMed  CAS  Google Scholar 

  46. Reuning RH, Geraets DR, Rocci Jr ML, et al. Digoxin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver: Applied Therapeutics, 1992: 20–1–48

    Google Scholar 

  47. Wofford JL, Ettinger WH. Risk factors and manifestations of digoxin toxicity in the elderly. Am J Emerg Med 1991; 9Suppl. 1: 11–5

    Article  PubMed  CAS  Google Scholar 

  48. Gault MH. Digitalis and renal failure [editorial]. Int J Artif Organs 1988; 11(3): 141–3

    PubMed  CAS  Google Scholar 

  49. Madrenas J, Codina S, Monné J, et al. Digoxin-like immunoreacting activity in the serum of patients on regular hemodialysis. Nephron 1986; 43: 303–4

    Article  PubMed  CAS  Google Scholar 

  50. Abe S, Yoshizawa M, Nakanishi N, et al. Electrocardiographic abnormalities in patients receiving hemodialysis. Am Heart J 1996; 131: 1137–44

    Article  PubMed  CAS  Google Scholar 

  51. Coyle JD, Lima JJ. Procainamide. In: Evans WE, Schentag JJ, Jusko WJ, et al., editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver: Applied Therapeutics, 1992: 22–1–33

    Google Scholar 

  52. Lowenthal DT. Pharmacokinetics of propranolol, quinidine, procainamide and lidocaine in chronic renal disease. Am J Med 1977; 62: 532–9

    Article  PubMed  CAS  Google Scholar 

  53. Harris L, McKenna WJ, Krikler SJ, et al. Renal elimination of amiodarone and its desethyl metabolite. Postgrad Med J 1983; 59: 440–2

    Article  PubMed  CAS  Google Scholar 

  54. Ueda CT. Quinidine. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver: Applied Therapeutics, 1992: 23–1–22

    Google Scholar 

  55. Harari D, Gurwitz JH, Minaker KL. Constipation in the elderly. J Am Geriatr Soc 1993; 41: 1130–40

    PubMed  CAS  Google Scholar 

  56. Mayersohn MB. Special pharmacokinetic considerations in the elderly. In: Evans WE, Schentag JJ, Jusko WJ, et al., editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver: Applied Therapeutics, 1992: 9–1–43

    Google Scholar 

  57. Romero Y, Evans JM, Fleming KC, et al. Constipation and fecal incontinence in the elderly population. Mayo Clin Proc 1996; 71: 81–92

    Article  PubMed  CAS  Google Scholar 

  58. Abyad A, Mourad F. Constipation: common-sense care of the older patient. Geriatrics 1996; 51(12): 28–36

    PubMed  CAS  Google Scholar 

  59. Gattuso JM, Kamm MA. Adverse effects of drugs used in the management of constipation and diarrhoea. Drug Saf 1994; 10(1): 47–65

    Article  PubMed  CAS  Google Scholar 

  60. Gloth III FM. Concerns with chronic analgesic therapy in elderly patients. Am J Med 1996; 101Suppl. 1A: 19–24S

    Google Scholar 

  61. Chan GLC, Matzke GM. Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. Drug Intell Clin Pharm 1987; 21: 773–83

    PubMed  CAS  Google Scholar 

  62. Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996; 31(6): 410–22

    Article  PubMed  CAS  Google Scholar 

  63. Fitzgerald J. Narcotic analgesics in renal failure. Conn Med 1991; 55(12): 701–4

    PubMed  CAS  Google Scholar 

  64. Miller RR. Propoxyphene: a review. Am J Hosp Pharm 1977; 34(4): 413–23

    PubMed  CAS  Google Scholar 

  65. Almirall J, Montoliu J, Torras A, et al. Propoxyphene-induced hypoglycemia in a patient with chronic renal failure. Nephron 1989; 53: 273–5

    Article  PubMed  CAS  Google Scholar 

  66. Gibson TP. Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl. Am J Med 1996; 101Suppl. 1A: 47–53S

    Google Scholar 

  67. Paganini EP. Hematologic abnormalities. In: Daugirdas JT, Ing TS, editors. Handbook of dialysis. 2nd ed. Boston: Little, Brown and Company, 1994: 445–68

    Google Scholar 

  68. Khan IH, Catto GRD. Long-term complications of dialysis: infection. Kidney Int 1993; 43Suppl. 41: S143–8

    Google Scholar 

  69. Vanholder R, Van Loo A, Dhondt AM, et al. Influence of uraemia and haemodialysis on host defense and infection. Nephrol Dial Transplant 1996; 11: 593–8

    Article  PubMed  CAS  Google Scholar 

  70. Raad II, Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis 1992; 15: 197–210

    Article  PubMed  CAS  Google Scholar 

  71. Almirall J, Gonzalez J, Rello J, et al. Infection of hemodialysis catheters: incidence and mechanisms. Am J Nephrol 1989; 9: 454–9

    Article  PubMed  CAS  Google Scholar 

  72. Raja RM. Vascular access for hemodialysis. Daugirdas JT, Ing TS, editors. Handbook of dialysis. 2nd ed. Boston: Little, Brown and Company, 1994: 53–77

    Google Scholar 

  73. St Peter WL, Redic-Kill KA, Halstenson CE. Clinical pharmacokinetics of antibiotics in patients with impaired renal function. Clin Pharmacokinet 1992; 22(3): 169–210

    Article  PubMed  CAS  Google Scholar 

  74. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333(24): 1618–23

    Article  PubMed  CAS  Google Scholar 

  75. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. Aconsensus statement. Am J Resp Crit Care Med 1995; 153: 1711–25

    Google Scholar 

  76. McCue JD. Pneumonia in the elderly, special considerations in a special population. Postgrad Med 1993; 94(5): 39–51

    PubMed  CAS  Google Scholar 

  77. Fox RA. Treatment recommendations for respiratory tract infections associated with aging. Drugs Aging 1993; 3(1): 40–8

    Article  PubMed  CAS  Google Scholar 

  78. Scott SR. AAPA 22nd Annual Conference, editor. Pneumonia: a leading cause of death in the elderly, but early diagnosis is easily missed. Medical Meeting Highlights, 1994

    Google Scholar 

  79. Janssens J-P, Gauthey L, Herrmann F, et al. Community-acquired pneumonia in older patients. J Am Geriatr Soc 1996; 44: 539–44

    PubMed  CAS  Google Scholar 

  80. Niederman MS, Bass Jr JB, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418–26

    PubMed  CAS  Google Scholar 

  81. Bergogne-Bérézin E. Treatment and prevention of nosocomial pneumonia. Chest 1995; 108(2 Suppl.): 26S–34S

    Article  PubMed  Google Scholar 

  82. Johnson DW, Fleming SJ. The use of vaccines in renal failure. Clin Pharmacokinet 1992; 22(6): 434–46

    Article  PubMed  CAS  Google Scholar 

  83. Keusch GT, Bart KJ. Immunization principles and vaccine use. In: Isselbacher KJ, Braunwald E, Wilson JD, et al., editors. Harrison’s principles of internal medicine. 13th ed. New York: McGraw-Hill, Inc., 1994: 498–511

    Google Scholar 

  84. Rodby RA, Trenholme GM. Vaccination of the dialysis patient. Semin Dialysis 1991; 4(2): 102–5

    Article  Google Scholar 

  85. Docci D, Cipolloni PA, Mengozzi S, et al. Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients: a two-year follow-up. Nephron 1992; 61: 352–3

    Article  PubMed  CAS  Google Scholar 

  86. Ono K, Kashiwagi S. Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients. Nephron 1991; 58: 47–51

    Article  PubMed  CAS  Google Scholar 

  87. Marangi AL, Giordano R, Montanaro A, et al. A successful two-step integrated protocol of anti-HBV vaccination in chronic uremia. Nephron 1992; 61: 331–2

    Article  PubMed  CAS  Google Scholar 

  88. Meurer SC, Dumann H, Meyer zum Büschenfelde K-H, et al. Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1989; I: 15–8

    Article  Google Scholar 

  89. St Peter WL, Mihalovic SW, Vargas-Ruiz M, et al. Chronic renal failure and end-stage renal disease. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: a pathophysiologic approach. Stamford (CT): Appleton & Lange, 1997: 913–57

    Google Scholar 

  90. Lam YWF, Banerji S, Hatfield C, et al. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997; 32: 30–57

    Article  PubMed  CAS  Google Scholar 

  91. Livornese Jr LL, Benz RL, Ingerman MJ, et al. Antibacterial agents in renal failure. Infect Dis Clin North Am 1995; 9: 591–614

    PubMed  Google Scholar 

  92. St Peter JV, Lambrecht LJ. Drug dosing in renal insufficiency and dialytic therapies. In: Carter BL, Angaran DM, Lake KD, et al., editors. Pharmacotherapy self-assessment program: respiratory, nephrology, gastroenterology. Kansas City (MO): American College of Clinical Pharmacy, 1996: 143–60

    Google Scholar 

  93. Reetze-Bonorden P, Böhler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Clin Pharmacokinet 1993; 24: 362–79

    Article  PubMed  CAS  Google Scholar 

  94. Bressolle F, Kinowski J-M, de la Coussaye JE, et al. Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet 1994; 26: 457–71

    Article  PubMed  CAS  Google Scholar 

  95. Bennett WM, Aronoff GR, Golper TA, et al., editors. Drug prescribing in renal failure. 3rd ed. Philadelphia: American College of Physicians, 1994

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA

    Wendy L. St Peter

  2. Division of Nephrology, Hennepin County Medical Center, 914 South 8th Street, Minneapolis, Minnesota, 55404, USA

    Wendy L. St Peter, Jennifer L. Clark & Ondrea M. Levos

Authors
  1. Wendy L. St Peter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer L. Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ondrea M. Levos
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

St Peter, W.L., Clark, J.L. & Levos, O.M. Drug Therapy in Haemodialysis Patients. Drugs & Aging 12, 441–459 (1998). https://doi.org/10.2165/00002512-199812060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199812060-00003

Keywords

Search

Navigation